PT-141

A melanocortin receptor agonist that enhances sexual desire by acting centrally in the brain rather than peripherally like PDE5 inhibitors. Works in both men and women.

Activates MC3R and MC4R receptors in the hypothalamus and limbic system to enhance sexual desire and arousal.

Unlike Viagra, which affects blood flow, PT-141 works in the brain on the pathways that regulate desire itself. It has been studied in both men and women with positive outcomes for both.

• Desire and arousal questionnaire scores
• MC3R and MC4R receptor activity
• Erectile response in male models
• Blood pressure response
• Time to onset and duration

• Female hypoactive sexual desire disorder
• Male erectile dysfunction
• Central mechanisms of sexual arousal

Derived from melanotan research at Palatin Technologies, where central arousal effects were observed as an unexpected finding, leading to FDA approval as Vyleesi for HSDD in women.

Men and women 25-60 seeking libido enhancement, women with low sexual desire, and men with performance concerns.

• Reconstitute with bacteriostatic water down the vial wall.
• Swirl gently until fully dissolved.
• Onset timing is protocol relevant, effects are not immediate.
• Store lyophilised at -20C, reconstituted at 4C.
• Protect from light.

• Central mechanism, distinct from vascular PDE5 references.
• Transient nausea and flushing reported in human trials.
• Transient blood pressure changes documented.
• Effective in both male and female study populations.